Hemolytic Disease of the Fetus and Newborn (HDFN) Epidemiology Study

The Hemolytic Disease of the Fetus and Newborn (HDFN) Epidemiology Study aims to analyze the epidemiology and clinical outcomes of HDFN using data from the PEDSnet database. HDFN, caused by maternal IgG alloantibodies that destroy fetal and neonatal erythrocytes, remains a critical concern despite advancements in prenatal care and prophylactic treatment. While Rh immunoprophylaxis has significantly reduced HDFN incidence, the condition still affects approximately 1-3 per 1,000 Rh-negative pregnancies, sometimes requiring invasive treatments like intrauterine transfusion (IUT) to manage fetal anemia.
This study will provide a comprehensive understanding of HDFN by analyzing neonates treated at PEDSnet hospitals. It will assess patient demographics, clinical characteristics, laboratory results, and treatment patterns, such as the use of IVIG, exchange transfusion, and phototherapy. The study will also explore maternal factors, including pregnancy history, blood biomarkers, and complications, alongside neonatal outcomes like hospital stays, NICU admissions, and growth and developmental milestones.
The findings will offer critical insights into HDFN’s natural history, maternal and fetal treatment patterns, and long-term pediatric outcomes, supporting future efforts to optimize care and improve outcomes for affected infants​.
The second phase of the Hemolytic Disease of the Fetus and Newborn (HDFN) study aims to further explore the real-world disease course of infants from HDFN-affected pregnancies, focusing on their healthcare experiences up to two years after birth. This phase will involve neonates and infants identified through the PEDSnet database, with additional data from affiliated institutions and existing cohorts, where available. The study will capture detailed antenatal, perinatal, and postnatal information to assess outcomes and healthcare utilization across different care settings.
The primary objectives are to describe the clinical disease course of these infants, compare disease progression based on prenatal and perinatal factors, and evaluate their healthcare resource utilization. The study will also investigate the contribution of specific antigens, especially in cases of non-Rhesus and non-ABO HDFN.
Exploratory aims include examining the same outcomes for infants with identified antigens, helping to refine treatment approaches and improve understanding of HDFN’s long-term impacts. The results from this phase will contribute to the development of improved clinical care strategies for infants affected by this condition​